CHICAGO -- Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition to standard therapy, a large randomized trial showed.

Median radiographic progression-free survival (rPFS) had yet to be reached in men who received niraparib (Zejula) along with abiraterone (Zytiga) and prednisone as compared with 29.5 months for patients who received placebo along with the androgen receptor pathway inhibitor (ARPI) combo. The risk of disease progression decreased by 37% in all patients treated with the PARP inhibitor and by 48% in the subgroup with BRCA1/2 mutations.

Niraparib also increased time to symptom worsening and yielded an early tren

See Full Page